Thinly traded nano cap Moleculin Biotech (NASDAQ:MBRX) jumps 41% premarket on robust volume in reaction to its plan to discuss accelerated approval
of Liposomal Annamycin with the FDA and EMA for the treatment of
relapsed/refractory acute myeloid leukemia, an Orphan Drug- and Fast
Track-tagged indication in the U.S.
It hopes to get sign-off on a single Phase 2 study to support the applications.
https://seekingalpha.com/news/3538481-moleculin-bio-up-41-premarket-on-potential-accelerated-approval-of-annamycin
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.